Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
V stat'e proveden obzor literatury po optimizacii putey vvedeniya lekarstvennyh sredstv. Pro- veden analiz osnovnyh deystvuyuschih sposobov dostavki farmakologicheskih preparatov s opisaniem ih preimuschestv i nedostatkov. Bolee shiroko osveschen ingalyacionnyy put' vvedeniya, kak naibolee sovremennyy i perspektivnyy.
sposoby dostavki lekarstvennyh sredstv, ingalyacionnyy put' vvedeniya, sovremennyy sposob dostavki lekarstv, anesteziologiya, premedikaciya
1. Chong CR, Sullivan D J. New uses for old drugs. Nature 2007; 448: 645-646
2. Benni JM, Patil PA. J Basic Clin Physiol Pharmacol. Non-diabetic clinical applications of insulin.2016 Sep 1;27(5):445-56.
3. She P, Wang Y, Luo Z, Chen L, Tan R, Wang Y, Wu Y. Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa. Microbiologyopen. 2017 Nov 27.
4. World Health Organization. Development of Paediatric Medicines: Points to Consider in Formulation. Geneva, Switzerland: World Health Organization; 2012. WHO Technical Report Series, No. 970, Annex 5
5. European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. EMA/CHMP/QWP/805880/2012 Rev. 2
6. Bertram G.Kacung Bazisnaya i klinicheskaya farmakologiya v 2h tomah, 2 izdanie M:Binom 2007: tom 1, 75
7. Avinash Y Kaushik, Ajay K Tiwari, and Ajay Gaur Role of excipients and polymeric advancements in preparation of floating drug delivery systems Int J Pharm Investig. 2015 Jan-Mar; 5(1): 1-12.
8. Back DJ1, Rogers SM Review: first-pass metabolism by the gastrointestinal mucosa. Aliment Pharmacol Ther. 1987 Oct;1(5):339-57
9. Breitkreutz J, Wessel T, Boos J. 13. Dosage forms for oral drug administration. In: Choonara I, Nunn T, Kearns G, eds. Introduction to Paediatric and Perinatal Drug Therapy. Nottingham, UK: Nottingham University Press;2003:189-205
10. Marconati M, Raut S, Burbidge A, Engmann J, Ramaioli M An in vitro experiment to simulate how easy tablets are to swallow. Int J Pharm. 2017 Oct 18;535(1-2):27-37
11. Rudralingam M, Randall C, Mighell AJ The use of topical steroid preparations in oral medicine in the UK Br Dent J. 2017 Dec;223(9):633-638
12. van Hoogdalem E, de Boer AG, Breimer DD Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet. 1991 Jul;21(1):11-26.
13. Netter FH, Hansen JT, Atlas Human of Anatomy 3rd edition 2003: 300-303
14. de Boer AG, Moolenaar F, de Leede LG, Breimer DD Rectal drug administration: clinical pharmacokinetic considerations Clin Pharmacokinet. 1982 Jul-Aug;7(4):285-311
15. Quintana DS, Alvares GA, Hickie IB, Guastella AJ. Neurosci Biobehav Rev Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model. 2015; 49: 182-192.
16. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration Neuroscience 2004; 127: 481-496.
17. Yamamoto A, Iseki T, Ochi-Sugiyama M, Okada N, Fujita T, Muranishi S. Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites. J Control Release 2001; 76: 363-374.
18. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM et al Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research . Psychoneuroendocrinology 2013; 38: 612-625.
19. Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy 2008; 28: 875-882.
20. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003 May-Aug;6(2):252-73.
21. Rosenbaum SE, Basic pharmacokinetics and pharmacodynamics, 2nd Edition. Hoboken, New Jersey : John Wiley & Sons, Inc., 2017.
22. Gradon L., Sosnowski T.R. Formation of particles for dry powder inhalers. Advanced Powder Technology Volume 25, Issue 1, January 2014: 43-55.
23. Tuncer DI, Nevin C. Controlled Delivery of Peptides and Proteins. Curr Pharm Des. 2007;13:99-117
24. Ma JKH, Bhat M, Rojanasakul Y Drug metabolism and enzyme kinetics in the lung. In: Lenfant C, editor. Inhalation aerosols. Physical and biological basis for therapy. New York: Marcel Dekker Inc.; 1996. pp. 155-195. 94.
25. Sapin M.R., Bocharov V.Ya., Nikityuk D.B., Satyukova G.S., Selin Yu.M., Spirin B.A. Anatomiya cheloveka v 2h tomah, 5 izd., M.Medicina 2001: tom 2, 221-226
26. Patton JS Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery Rev. 1996;19:3-36.
27. Smaldone GC, Perry RJ, Bennett WD, Messina MS, Zwang J, Ilowite J. Interpretation of ‘24 hour lung retention’ in studies of mucociliary clearance. J Aerosol Med. 1988;1:11-20.
28. Evans CM, Koo JAS. Airway mucus: the good, the bad, the sticky. Pharmacol Therapeut. 2009;121:332-48.
29. Londahl J, Massling A, Pagels J, Swietlicki E, Vaclavik E, Loft S. Size-resolved respiratory-tract deposition of fine and ultrafine hydrophobic and hygroscopic aerosol particles during rest and exercise. Inhal. Toxicol. 19(2), 109-16 (2007).
30. Dunne RB, Shortt S. Comparison of bronchodilator administration with vibrating mesh nebulizer and standard jet nebulizer in the emergency department. Am J Emerg Med. 2017 Oct 31.
31. Tashkin DP, Ferguson GT, Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease, Tashkin and Ferguson Respiratory Research 2013, http://respiratory-research.com/content/14/1/49
32. Kerstjens Huib A.M., , Brand Paul L.P., Hughes MD., Robinson N. Jamie A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease N Engl J Med 1992; 327:1413-1419
33. Barker AF., Couch L., Fiel SB., Gotfried MH., Ilowite J., Meyer KC., O'donnell A. Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis American Journal of Respiratory and Critical Care Medicine Vol. 162, No. 2 | Aug 01, 2000
34. Ryan G, Singh M, Dwan K Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev. 2011;3: CD001021.
35. Kapustina V., Ovcharenko S. The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis European Respiratory Journal 2013 42
36. Poole Ph., Black PN., Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease, Cochrane Database Syst Rev. 2010; 2 (CD001287.)
37. Qiu Yuan-Hua, Chen En-Guo, Dai Yuan-Rong, Ren Zhen-Yi Efficacy and Safety of Domestic Inhaled N-acetyl-L-cysteine Solution in Mucolytic Therapy Chinese Pharmaceutical Journal 2012-21
38. Rozenberg O. A., Legochnyy surfaktant i ego primenenie pri zabolevaniyah legkih, Obschaya reanimatologiya, 2007, tom 3; №1
39. J.M.Borroa, A.Soléb, M.de la Torrea, A.Pastorb, R.Fernandeza, A.Saurab, M.Delgadoa, E.Monteb, D.Gonzaleza Efficiency and Safety of Inhaled Amphotericin B Lipid Complex (Abelcet) in the Prophylaxis of Invasive Fungal Infections Following Lung Transplantation Transplantation Proceedings Volume 40, Issue 9, November 2008, Pages 3090-3093
40. S. GargEmail authorJ. RosenstockB. L. SilvermanB. SunC. S. KonkoyA. de la PeñaD. B. Muchmore Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes Diabetologia May 2006, 49:891
41. Abigail L. Chua, Stephen Silberstein Inhaled drug therapy development for the treatment of migraine Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 13
42. Roncero Carlos, Ros-Cucurull Elena, Grau-López Lara, Fadeuilhe Christian, Casas Miguel, Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series Clinical Neuropharmacology: July/August 2016 - Volume 39 - Issue 4 - p 206-209
43. Timothy Aksamit, Tiemo-JoergBandel, MargaritaCriollo, Anthony De Soyza, J Stuart Elborn, ElisabethOperschall, Eva Polverino The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis Contemporary Clinical Trials Volume 58, July 2017, Pages 78-85
44. Kenneth N. Olivier, David E. Griffith, Gina Eagle, John P. McGinnis II, Liza Micioni, Keith Liu, Charles L. Daley, Kevin L. Winthrop, Stephen Ruoss, Doreen J. Addrizzo-Harris, Patrick A. Flume, Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease, American Journal of Respiratory and Critical Care Medicine, Vol. 195, No. 6 | Mar 15, 2017
45. Onur Turan, Pakize Ayse Turan, Arzu Miric Parameters affecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma, Geriatrics & Gerontology International ,Volume 17, Issue 6 June 2017 Pages 999-1005
46. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med. 2017;17(1):31
47. Tony Velkov, Nusaibah Abdul Rahim, Qi (Tony) Zhou, Hak-Kim Chan, Jian Lia Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead, Adv Drug Deliv Rev. 2015 May; 85: 65-82
48. Jia-Wei Yang, Li-Chao Fan, Hai-Wen Lu, Xia-Yi Miao, Bei Mao, Jin-Fu Xu Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis, The Clinical Respiratory Journal, Volume 10, Issue 6 November 2016 Pages 731-739
49. Jonkman K, Duma A, Velzen M, Dahan A. Br J Anaesth., Ketamine inhalation. 2017 Feb;118(2):268-269.
